EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2015

  • ID: 3387862
  • Report
  • July 2015
  • 98 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AB Science SA
  • Biogen, Inc.
  • Genzyme Corporation
  • Glialogix, Inc.
  • MedDay
  • Merck KGaA
  • MORE
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2015

Summary

The report ‘Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2015’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Secondary Progressive Multiple Sclerosis (SPMS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Secondary Progressive Multiple Sclerosis (SPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science SA
  • Biogen, Inc.
  • Genzyme Corporation
  • Glialogix, Inc.
  • MedDay
  • Merck KGaA
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Secondary Progressive Multiple Sclerosis (SPMS) Overview
Therapeutics Development
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Overview
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Comparative Analysis
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics under Development by Companies
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Secondary Progressive Multiple Sclerosis (SPMS) - Products under Development by Companies
Secondary Progressive Multiple Sclerosis (SPMS) - Companies Involved in Therapeutics Development
AB Science SA
Biogen, Inc.
Daval International Limited
Genzyme Corporation
Glialogix, Inc.
Immune Response BioPharma, Inc.
Innate Immunotherapeutics Limited
Kyorin Pharmaceutical Co., Ltd.
MedDay
Merck KGaA
Novartis AG
Opexa Therapeutics, Inc.
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aimspro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ApE - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATXMS-1467 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
biotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DC-TAB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLX-1112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-402668 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imilecleucel-t - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IR-902 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIS-416 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
natalizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
opicinumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OSX-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
siponimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Secondary Progressive Multiple Sclerosis (SPMS) - Recent Pipeline Updates
Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products
Secondary Progressive Multiple Sclerosis (SPMS) - Product Development Milestones
Featured News & Press Releases
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC
Oct 07, 2014: Update on Innate’s Phase 2B trial and other recent activities
Aug 19, 2014: Innate’s Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval
Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis
Jun 18, 2014: Compassionate Use Programme Update
May 13, 2014: Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis
Apr 15, 2014: Innate Immunotherapeutics confirms Phase 2B trial on track and on budget
Mar 11, 2014: Innate Immunotherapeutics receives EU patent protection for use of MIS416 to treat or prevent radiation injury
Feb 03, 2014: Dr Larry Steinman, renowned multiple sclerosis specialist at Stanford University, endorses newly published MIS416 therapy validation in animal studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2015
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by AB Science SA, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Biogen, Inc., H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Daval International Limited, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Genzyme Corporation, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Glialogix, Inc., H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Immune Response BioPharma, Inc., H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Innate Immunotherapeutics Limited, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedDay, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Merck KGaA, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Novartis AG, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Opexa Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Recent Pipeline Updates, H2 2015
Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2015
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
3 of 4
AB Science SA
Biogen, Inc.
Daval International Limited
Genzyme Corporation
Glialogix, Inc.
Immune Response BioPharma, Inc.
Innate Immunotherapeutics Limited
Kyorin Pharmaceutical Co., Ltd.
MedDay
Merck KGaA
Novartis AG
Opexa Therapeutics, Inc.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll